MRTX News and Press, Mirati Therapeutics Inc. From 02/16/22

Mirati Therapeutics (NASDAQ:MRTX) is trading ~7% lower in the pre-market on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) accepted its marketing application for KRASG12C inhibitor adagrasib for accelerated approval. The New Drug Application (...

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer PR Newswire SAN DIEGO , Feb. 15, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc...

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022 PR Newswire SAN DIEGO , Feb. 14, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage ta...

The major U.S. equity averages managed to build strength throughout the session on Tuesday, leading to larger-than-1% advances in the Dow and Nasdaq. The S&P 500 trailed a bit but still posted a notable climb. However, even with the gains, stocks remained in a general holding pattern afte...

Gainers: Society Pass (NASDAQ:SOPA) +57%. Tritium DCFC Limited (NASDAQ:DCFC) +36%. Peloton Interactive (NASDAQ:PTON) +29%. IN8bio (NASDAQ:INAB) +22%. Teradata Corporation (NYSE:TDC) +24%. Atomera (NASDAQ:ATOM) +21%. BioCardia (NASDAQ:BCDA) +20%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +18%. ...

Shares of Mirati Therapeutics (MRTX -13.2%) are down significantly today as a consequence of poor quarterly sales of Amgen's (AMGN +8.4%) Lumakras (sotorasib) non-small cell lung cancer ("NSCLC") treatment. Mirati's adagrasib is a rival KRAS inhibitor in late-stage development also for NSCLC....

Gainers: Haemonetics (NYSE:HAE) +13%. Second Sight Medical Products (NASDAQ:EYES) +8%. Catalyst Pharmaceuticals (NASDAQ:CPRX) +6%. Quotient (NASDAQ:QTNT) +5%. Ocuphire Pharma (NASDAQ:OCUP) +3%. Losers: Pulse Biosciences (NASDAQ:PLSE) -36%. Karyopharm Th...

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences PR Newswire SAN DIEGO , Feb. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare co...

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers PR Newswire SAN DIEGO , Jan. 21, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targ...

Shares of oncology-focused biotech Mirati Therapeutics (NASDAQ: MRTX) have stumbled across the past few days, with the stock trading in the red by nearly 11% week to date as of Thursday's close. A spot of good news from a product that rivals its key pipeline drug seemed to be the fo...